Effect of pembrolizumab (pembro) monotherapy versus brentuximab vedotin (BV) on patients (Pts) with relapsed/refractory classical Hodgkin lymphoma (R/R cHL): exploratory analysis of the randomized, phase 3 KEYNOTE-204 study by prior lines of therapy

John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A. Johnson, Laura Maria Fogliatto, Iara Goncalves, Jose de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Article number624
Pages (from-to)12
Number of pages1
JournalBlood
Volume136
Issue numberSupplement 1
DOIs
Publication statusPublished - 5 Nov 2020
Externally publishedYes
Event62nd American Society of Hematology Annual Meeting and Exposition - Virtual
Duration: 5 Dec 20208 Dec 2020

Cite this